BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 276 filers reported holding BIO-TECHNE CORP in Q2 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $317,000 | -48.5% | 654 | -52.1% | 0.03% | -44.6% |
| Q2 2021 | $615,000 | +1.2% | 1,366 | -4.0% | 0.06% | +3.7% |
| Q1 2021 | $608,000 | +27.7% | 1,423 | -5.0% | 0.05% | +17.4% |
| Q4 2020 | $476,000 | +24.9% | 1,498 | -2.5% | 0.05% | +15.0% |
| Q3 2020 | $381,000 | -6.4% | 1,536 | -0.4% | 0.04% | -11.1% |
| Q2 2020 | $407,000 | +38.0% | 1,542 | -0.8% | 0.04% | +73.1% |
| Q1 2020 | $295,000 | -31.4% | 1,554 | -20.7% | 0.03% | +30.0% |
| Q4 2019 | $430,000 | +1.9% | 1,959 | -9.1% | 0.02% | 0.0% |
| Q3 2019 | $422,000 | -6.0% | 2,155 | +0.0% | 0.02% | -9.1% |
| Q2 2019 | $449,000 | +5.6% | 2,154 | +0.7% | 0.02% | 0.0% |
| Q1 2019 | $425,000 | +38.4% | 2,140 | +0.8% | 0.02% | +15.8% |
| Q4 2018 | $307,000 | -33.0% | 2,123 | -5.5% | 0.02% | -13.6% |
| Q3 2018 | $458,000 | +38.8% | 2,246 | +0.7% | 0.02% | +37.5% |
| Q2 2018 | $330,000 | -3.5% | 2,230 | -1.5% | 0.02% | 0.0% |
| Q1 2018 | $342,000 | +2.1% | 2,263 | -12.5% | 0.02% | +45.5% |
| Q4 2017 | $335,000 | +1.8% | 2,586 | -5.1% | 0.01% | 0.0% |
| Q3 2017 | $329,000 | +3.5% | 2,724 | +0.6% | 0.01% | 0.0% |
| Q2 2017 | $318,000 | +20.5% | 2,708 | +4.1% | 0.01% | +22.2% |
| Q1 2017 | $264,000 | +13.3% | 2,602 | +14.9% | 0.01% | 0.0% |
| Q4 2016 | $233,000 | -12.1% | 2,264 | -6.3% | 0.01% | 0.0% |
| Q3 2016 | $265,000 | +29.9% | 2,417 | +33.3% | 0.01% | +12.5% |
| Q2 2016 | $204,000 | – | 1,813 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |